Bryn Williams-Jones

SVP Drug Discovery

Bryn Williams-Jones is BenevolentAI’s Senior Vice President Drug Discovery and is responsible for driving the application of our AI-enabled drug discovery Platform – the Benevolent Platform™ – to generate new target hypotheses for different diseases across the BenevolentAI portfolio. In this way, his role is key in bringing together our biology and AI capabilities.

Before joining BenevolentAI, Bryn led the Open PHACTS project of the Innovative Medicines Initiative (a private partnership between the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the EU), and continues as CEO of the Open PHACTS Foundation, which brings together freely accessible data in an open semantic web infrastructure to support drug discovery. Prior to that Bryn worked at Pfizer across a wide range of therapeutic areas applying data and computational science to early drug discovery hypothesis generation. Here he provided global thought leadership on applying computational biology to understanding the biological mechanisms of diseases and improving target identification. Whilst at Pfizer, he also served as Co-Chair of the EFPIA Knowledge Management Affinity Group, which identifies knowledge management challenges and opportunities in collaborative drug discovery and development.